BioSpace News Archive

Molecure S.A. a clinical stage biotechnology company developing first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases announces first half results for the period ended 30 June 2023.

Microbix Biosystems Inc. announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 29 to October 1, 2023.

Codexis, Inc., a leading enzyme engineering company, announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award.

Thymmune Therapeutics announced that the U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health has awarded up to $37 million in funding to the Thymus Rejuvenation project.

Capricor Therapeutics announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy.

Outlook Therapeutics, Inc. announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration to discuss the Complete Response Letter dated August 29, 2023 regarding the Biologics License Application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

Geron Corporation (Nasdaq: GERN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).

Cimeio Therapeutics today announced the publication of research in the Journal of Experimental Medicine showing that epitope edited human hematopoietic stem cells (HSCs) can be protected from targeted immunotherapies.

Lexaria Bioscience Corp. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock in a registered direct offering.

RaySearch Laboratories AB is pleased to announce that the longterm collaboration/partnership with the innovative center EBG MedAustron GmbH in Wiener Neustadt in Austria will be further expanded through a new research agreement.